A STERILISATION implant used on the NHS has attracted "serious" safety concerns from health experts.
The Essure device, manufactured by pharmaceutical giant Bayer, has already attracted huge controversy in the US after regulators received more than 5,000 complaints from women.
Two law firms in the UK, Leigh Day and Irwin Mitchell, now say they have been contacted by women who say their health has been negatively affected by the implant.
The Medical and Healthcare products Regulatory Agency (MHRA) said it could not disclose the number of reports it had received regarding Essure but it was aware of some problems among users.
It said it had no current information to suggest the Essure device was unsafe.
In a new study published in the British Medical Journal (BMJ), experts from Cornell University in New York said women who have the device have a 10 times higher risk of needing another operation.
They compared results for 8,048 patients undergoing sterilisation with Essure with 44,278 undergoing usual laparoscopic sterilisation.
They wrote: "At one year after surgery, hysteroscopic sterilisation (Essure) was ... associated with a substantially increased risk of re-operation compared with laparoscopic sterilisation."
The authors warned that this increased rate was a "serious safety concern".
The Food and Drug Administration (FDA) in the US is reviewing the benefits of Essure after it received thousands of reports about the device.
American campaigner Erin Brockovich has also been working in the US to raise awareness about what she considers to be the dangers of Essure.
Essure differs to more traditional sterilisation by blocking the fallopian tubes and is less invasive to have installed.
The implants are usually inserted under local anaesthetic. A narrow tube with a telescope at the end, called a hysteroscope, is passed through the woman's vagina and cervix.
A tiny piece of titanium metal is then put into the hysteroscope, then into each of the fallopian tubes.
The implant causes the fallopian tube to form scar tissue around it, which eventually blocks the tube.
A statement from the MHRA said: "We currently have no information to suggest that Essure devices used in the UK are unsafe to use.
"We keep all such devices under review and will consider this latest evidence and offer updated advice where appropriate."
FDA data shows in 482 cases, patients said the device had migrated to elsewhere in their body while 259 reported the device breaking.
Five reports involved the deaths of unborn babies in women who had become pregnant despite having Essure. Four deaths in women with the device were also reported.
A statement from Bayer said: "Essure is a highly effective birth control option with a positive benefit-risk profile for women who have completed their families and want permanent contraception with a non-surgical procedure.
"Over a decade of research and development and a decade of real world experience supports the safety and efficacy of Essure."
It said an Essure confirmation test is administered three months after the procedure to determine whether or not a woman's fallopian tubes are blocked.
This test "may detect unsatisfactory device placement, resulting in the need for 're-operation' to remove the device and/or complete a tubal ligation if sterilisation is still desired," the statement said.
"Because there is no confirmation test that could identify potential failure of a laparoscopic tubal ligation procedure, it stands to reason that the comparative re-operation rate would be lower."
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here